SlideShare una empresa de Scribd logo
1 de 45
Gastrointestinal Pharmacotherapy Sarah Nelson, Pharm.D. March 3, 2009
Objectives ,[object Object],[object Object],[object Object],[object Object]
Gastrointestinal tract http://www.nationmaster.com/encyclopedia/Gastrointestinal-tract
Disorders of the Esophagus and Stomach ,[object Object],[object Object],[object Object],[object Object],[object Object],Ali, T. Miner, P. New Developments in gastroesophageal reflux disease diagnosis and therapy.  Curr Opin in Gastroenterology.  2008;24:502-508
Gastric Secretion http://www.nature.com/nrd/journal/v2/n2/images/nrd1010-f2.gif
Stomach Anatomy http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/19223.jpg
Defense Mechanisms ,[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
GERD ,[object Object],[object Object],[object Object],[object Object],[object Object],Ali, T. Miner, P. New Developments in gastroesophageal reflux disease diagnosis and therapy.  Curr Opin in Gastroenterology.  2008;24:502-508
Epidemiology ,[object Object],[object Object],[object Object],Shaheen, N., Ransohoff, D.F. Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review.  J AMA . 2002;287(15):1972-1981
Risk Factors for GERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Stages of GERD Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006. ,[object Object],[object Object],[object Object],[object Object],III ,[object Object],[object Object],[object Object],II  ,[object Object],[object Object],[object Object],[object Object],I (NERD) Medical Management Description Stage
Treatment of GERD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Antacids ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Site GI chapter
Antacids ,[object Object],[object Object],[object Object],[object Object],[object Object],Site GI chapter
Antacids ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Site GI chapter
H 2 -Receptor Antagonists ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
H 2 -Receptor Antagonists ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
H 2 -Receptor Antagonists ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Proton Pump Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Proton Pump Inhibitors Site GI chapter 20mg daily 20mg daily Rabeprazole (Aciphex ® ) 20-40mg daily 40mg daily Pantoprazole (Protonix ® ) 15 mg daily 15-30mg daily Lansoprazole (Prevacid ® ) 20mg daily 20-40mg daily Esomeprazole (Nexium ® ) 20mg daily 20-40mg daily Omeprazole (Prilosec ® ) Prevention Healing  Drug
Proton Pump Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Miscellaneous ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Site GI chapter
Complications of GERD ,[object Object],[object Object],[object Object],[object Object],[object Object],Shaheen, N., Ransohoff, D.F. Gastroesophageal Reflux, Barret Esophagus, and Esophageal Cancer: Scientific Revies.  J AMA . 2002;287(15):1972-1981 Dougherty, R., Fahy, J. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype.  Clinical and Experimental Allergy.  2009;39(2):193-202
H. Pylori Infection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
H. Pylori Infection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Acid-rebound Phenomenon ,[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Disorders of the Lower GI Tract ,[object Object],[object Object]
Gastrointestinal Motility ,[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
GI Motility http://img.tfd.com/vet/thumbs/gr294.jpg ,[object Object],[object Object],[object Object],[object Object]
Constipation ,[object Object],[object Object],[object Object],[object Object],[object Object],Cash, B. et al. Update on the Management of Adults with Chronic Idiopathic Constipation.  The Journal of Family Practice.  2007;56(6):S13-20
Constipation http://www.helpfulhealthtips.com/Images/C/constipation1.jpg
Causes of Constipation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Treatment of Constipation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Bulk-Forming Laxatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Stimulant Laxatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006. Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Hyperosmotic Laxatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006. Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Stool Softeners/Lubricants ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Diarrhea  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Diarrhea http://www.ghi.com/WebMD/topics/diarrhea.jpg
Opioid Derivatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Site GI chapter Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Adsorbents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Bismuth Salicylate ,[object Object],[object Object],[object Object],[object Object],[object Object],Brunton, Laurence.  Goodman & Gillman’s The Pharmacological Basis of Therapeutics .  11 th  Edition. USA; McGraw-Hill Company, 2006.
Probiotics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Dipiro, Joseph et al.  Pharmacotherapy: A Pathophysiologic Approach . 6 th  Edition. USA; McGraw-Hill Company, 2005.
Conclusion ,[object Object],[object Object],[object Object]
[object Object]

Más contenido relacionado

La actualidad más candente

Anti diarrheals and laxatives
Anti diarrheals and laxativesAnti diarrheals and laxatives
Anti diarrheals and laxatives
Umair hanif
 
Gastrointestinal drugs
Gastrointestinal  drugsGastrointestinal  drugs
Gastrointestinal drugs
Umair hanif
 

La actualidad más candente (20)

Drugs Used In Disorders of Gastrointestinal System
Drugs Used In Disorders of Gastrointestinal SystemDrugs Used In Disorders of Gastrointestinal System
Drugs Used In Disorders of Gastrointestinal System
 
Antidiarrheals drug
Antidiarrheals drugAntidiarrheals drug
Antidiarrheals drug
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
Proton pump inhibitors (ppi)
Proton pump inhibitors (ppi)Proton pump inhibitors (ppi)
Proton pump inhibitors (ppi)
 
Antiemetics, emetics
Antiemetics, emeticsAntiemetics, emetics
Antiemetics, emetics
 
Drugs acting on G.I. system
Drugs acting on G.I. systemDrugs acting on G.I. system
Drugs acting on G.I. system
 
Antacids and antiulcer drugs
Antacids and antiulcer drugsAntacids and antiulcer drugs
Antacids and antiulcer drugs
 
Drugs for constipation and diarrhea
Drugs for constipation and diarrheaDrugs for constipation and diarrhea
Drugs for constipation and diarrhea
 
ANTIEMETICS (GIT - 1)
ANTIEMETICS (GIT -  1)ANTIEMETICS (GIT -  1)
ANTIEMETICS (GIT - 1)
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
Anti diarrheals and laxatives
Anti diarrheals and laxativesAnti diarrheals and laxatives
Anti diarrheals and laxatives
 
Gastrointestinal drugs
Gastrointestinal  drugsGastrointestinal  drugs
Gastrointestinal drugs
 
Proton Pump Inhibitor (PPI)
Proton Pump Inhibitor (PPI)Proton Pump Inhibitor (PPI)
Proton Pump Inhibitor (PPI)
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
drugs acting on autonomic nervous system
drugs acting on autonomic nervous systemdrugs acting on autonomic nervous system
drugs acting on autonomic nervous system
 
Anti emetics
Anti  emeticsAnti  emetics
Anti emetics
 
pharmacology of peptic ulcer disease
pharmacology of peptic ulcer diseasepharmacology of peptic ulcer disease
pharmacology of peptic ulcer disease
 
Gastrointestinal drugs - Pharmacology
Gastrointestinal  drugs - PharmacologyGastrointestinal  drugs - Pharmacology
Gastrointestinal drugs - Pharmacology
 
Pantoprazole + Domperidone Pharmacology
Pantoprazole + Domperidone PharmacologyPantoprazole + Domperidone Pharmacology
Pantoprazole + Domperidone Pharmacology
 
Antiulcer drugs
Antiulcer drugsAntiulcer drugs
Antiulcer drugs
 

Destacado

Drugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractDrugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tract
Bruno Mmassy
 
Pharmacology powerpoint git drugs
Pharmacology powerpoint  git drugsPharmacology powerpoint  git drugs
Pharmacology powerpoint git drugs
Fred Ecaldre
 
Gi system pharmacology
Gi system pharmacologyGi system pharmacology
Gi system pharmacology
gloworm279
 
The Digestive System Powerpoint
The Digestive System   PowerpointThe Digestive System   Powerpoint
The Digestive System Powerpoint
angellacx
 
Blood supply and venous drainage of the gastro-intestinal tract and liver
Blood supply and venous drainage of the gastro-intestinal tract and liverBlood supply and venous drainage of the gastro-intestinal tract and liver
Blood supply and venous drainage of the gastro-intestinal tract and liver
meducationdotnet
 

Destacado (20)

Drugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractDrugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tract
 
Pharmacology powerpoint git drugs
Pharmacology powerpoint  git drugsPharmacology powerpoint  git drugs
Pharmacology powerpoint git drugs
 
GIT pharmacology
GIT pharmacologyGIT pharmacology
GIT pharmacology
 
Pharmacology Git Drugs
Pharmacology   Git DrugsPharmacology   Git Drugs
Pharmacology Git Drugs
 
Gastrointestinal disease lecture(ppt)
Gastrointestinal disease lecture(ppt)Gastrointestinal disease lecture(ppt)
Gastrointestinal disease lecture(ppt)
 
Gi system pharmacology
Gi system pharmacologyGi system pharmacology
Gi system pharmacology
 
Gastrointestinal physiology
Gastrointestinal physiologyGastrointestinal physiology
Gastrointestinal physiology
 
Pharmacology of Gastrointestinal Diseases
Pharmacology of Gastrointestinal DiseasesPharmacology of Gastrointestinal Diseases
Pharmacology of Gastrointestinal Diseases
 
Digestive Pharmacology/ Drug acting on GIT
Digestive Pharmacology/ Drug acting on GITDigestive Pharmacology/ Drug acting on GIT
Digestive Pharmacology/ Drug acting on GIT
 
Digestion System's Diseases
Digestion System's DiseasesDigestion System's Diseases
Digestion System's Diseases
 
Peptic ulcer treatment
Peptic ulcer treatmentPeptic ulcer treatment
Peptic ulcer treatment
 
The Digestive System Powerpoint
The Digestive System   PowerpointThe Digestive System   Powerpoint
The Digestive System Powerpoint
 
GIT 4th motility 2016.
GIT 4th motility 2016.GIT 4th motility 2016.
GIT 4th motility 2016.
 
Intestinal peristalsis physiology and motility disorders
Intestinal peristalsis physiology and motility disordersIntestinal peristalsis physiology and motility disorders
Intestinal peristalsis physiology and motility disorders
 
GI System, Ulceration and Role of PPI
GI System, Ulceration and Role of PPIGI System, Ulceration and Role of PPI
GI System, Ulceration and Role of PPI
 
Management Of The Morbidly Obese
Management Of The Morbidly ObeseManagement Of The Morbidly Obese
Management Of The Morbidly Obese
 
Unit 1 a&p digestive system cti
Unit 1 a&p digestive system ctiUnit 1 a&p digestive system cti
Unit 1 a&p digestive system cti
 
Formulation factors affecting drug absorption
Formulation factors affecting drug absorptionFormulation factors affecting drug absorption
Formulation factors affecting drug absorption
 
Blood supply and venous drainage of the gastro-intestinal tract and liver
Blood supply and venous drainage of the gastro-intestinal tract and liverBlood supply and venous drainage of the gastro-intestinal tract and liver
Blood supply and venous drainage of the gastro-intestinal tract and liver
 
GI pharmacology
GI pharmacologyGI pharmacology
GI pharmacology
 

Similar a Gastrointestinal Pharmacotherapy.Ppt Final

Acid peptic disease nsaids
Acid peptic disease  nsaidsAcid peptic disease  nsaids
Acid peptic disease nsaids
raj kumar
 
Drugs acting on GIT.pptx
Drugs acting on GIT.pptxDrugs acting on GIT.pptx
Drugs acting on GIT.pptx
wakogeleta
 

Similar a Gastrointestinal Pharmacotherapy.Ppt Final (20)

Acid peptic disease nsaids
Acid peptic disease  nsaidsAcid peptic disease  nsaids
Acid peptic disease nsaids
 
Gerd presentation ( Case study )
Gerd presentation ( Case study )Gerd presentation ( Case study )
Gerd presentation ( Case study )
 
Gastroesophageal disease (GERD) in Adults
Gastroesophageal disease (GERD) in AdultsGastroesophageal disease (GERD) in Adults
Gastroesophageal disease (GERD) in Adults
 
Pharmacology H2 antagonist psp Amrita.pptx
Pharmacology H2 antagonist  psp Amrita.pptxPharmacology H2 antagonist  psp Amrita.pptx
Pharmacology H2 antagonist psp Amrita.pptx
 
GIT 1.pptx
GIT 1.pptxGIT 1.pptx
GIT 1.pptx
 
Gerd by Dr.Reda Emam Amer
Gerd by Dr.Reda Emam AmerGerd by Dr.Reda Emam Amer
Gerd by Dr.Reda Emam Amer
 
DRUGS ACTING ON GIT.pdf
DRUGS ACTING ON GIT.pdfDRUGS ACTING ON GIT.pdf
DRUGS ACTING ON GIT.pdf
 
Drugs used-in-peptic-ulcer
Drugs used-in-peptic-ulcerDrugs used-in-peptic-ulcer
Drugs used-in-peptic-ulcer
 
Drugs affecting Gastro Intestinal function
Drugs affecting Gastro Intestinal functionDrugs affecting Gastro Intestinal function
Drugs affecting Gastro Intestinal function
 
GERD &STRESS
GERD &STRESSGERD &STRESS
GERD &STRESS
 
GERD &STRESS
GERD &STRESSGERD &STRESS
GERD &STRESS
 
9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system
 
Drugs acting on GIT.pptx
Drugs acting on GIT.pptxDrugs acting on GIT.pptx
Drugs acting on GIT.pptx
 
NurseReview.Org - Pharmacology Git Drugs
NurseReview.Org - Pharmacology Git DrugsNurseReview.Org - Pharmacology Git Drugs
NurseReview.Org - Pharmacology Git Drugs
 
Presentation on peptic ulcer
Presentation on peptic ulcerPresentation on peptic ulcer
Presentation on peptic ulcer
 
GIT drugs
GIT drugsGIT drugs
GIT drugs
 
Current Trends in Management of Gastroesophageal Reflux Disease
Current Trends in Management of Gastroesophageal Reflux DiseaseCurrent Trends in Management of Gastroesophageal Reflux Disease
Current Trends in Management of Gastroesophageal Reflux Disease
 
ppt gerd.ppt
ppt gerd.pptppt gerd.ppt
ppt gerd.ppt
 
Nursing_3703_digestive_system_drugs (1).ppt
Nursing_3703_digestive_system_drugs (1).pptNursing_3703_digestive_system_drugs (1).ppt
Nursing_3703_digestive_system_drugs (1).ppt
 
Nursing_3703_digestive_system_drugs.ppt
Nursing_3703_digestive_system_drugs.pptNursing_3703_digestive_system_drugs.ppt
Nursing_3703_digestive_system_drugs.ppt
 

Gastrointestinal Pharmacotherapy.Ppt Final

Notas del editor

  1. Good afternoon, my name is Sarah, I am a pharmacy practice resident at VCU . . . I will be speaking about medications related to disorders of the GI tract. This is a very broad category, but we will be following the assigned chapter closely. I will talk more in depth about GERD (acid reflux), than I will about constipation or diarrhea, as determined by the prevalence of these disorders in the American patient population. Please feel free to interrupt me with questions at any time .
  2. We will focus first on the process of acid secretion in the GI tract, most notably the stomach. After we have an understanding of the cellular key players in acid secretion, we will discuss the various medications available and how each works. As this is the topic I would like to focus on today, we will talk about dosages of medications, as well as side effects and their place in treatment. We will also discuss complications of Gird We will then turn our attention to the lower GI tract and discuss the mechanism of motility, disorders of motility, and what treatment options we have for those patients.
  3. We will not be covering all diagnoses of the GI tract that require medication for management. We will focus on the most frequently diagnosed and utilized medications, including GERD/NERD, diarrhea and constipation, and a few miscellaneous items. POINT OUT UPPER GI AND LOWER GI TRACT DEVIATION
  4. Starting with the upper GI tract, there are 2 main categories of disease states related to acid secretion. The first is GERD, which can span a wide range of symptoms and complications. The first, dyspepsia, is also known as heartburn or NERD. This occurs with acid and stomach contents backs into the esophagus without major irritation or erosion of the esophageal lining. Repeated contact with an acidic substance eventually leads to erosion, creating an esophagitis. Esophagitis or inflammation of the stomach lining can lead to a full ulceration in the epithelial lining, which can be associated with a H. pylori bacterial infection. Pts that have H. pylori w/o and ulcer and H. pylori with an ulcer should both be treated, as H. pylori has been identified as a risk factor for forming an ulcer
  5. Gastric acid secretion is a continuous process in which multiple central and peripheral factors contribute to a common endpoint, secretion of hydrogen ions by parietal cells. Neuronal (acetylcholine), paracrine (histamine), and endocrine (gastrin) factors all regulate acid secretion. Receptors for Ach, histamine and gastrin are on the basolateral membrane of parietal cells in the body and fundus of the stomach. Ach: stimulates gastic acid secretion via response to sight, smell, taste, or anticipation of food. It also increases the release of histamine from the enterochromaffin-like (ECL) cells in the fundus of the stomach, and of gastrin in the gastric antrum. Histamine: ECL cells are close to parietal cells, histamine is released and diffuses to parietal cells, activating histamine receptors. Gastrin: most potent inducer of acid secretion. CNS activation, distention of stomach, and gastric contents stimulate gastrin release. Gastrin induces ECL cells to release histamine, and also (to a lesser extent), stimulates direct acid secretion.
  6. Point out fundus, antrum, and LES
  7. Defense mechanisms are required to protect the esophagus and stomach from the extremely high concentration of hydrogen ions LES: prevents the reflux of contents into the esophagus-talk about this causing dyspepsia, certain foods trigger relaxation of the LES Stimulated by prostaglandin E2 and I2, soluble gastric mucus is secreted and forms an insoluble gel on the mucosal surface of the stomach ASA, alcohol, and other drugs that inhibit prostaglandin secretion inhibit the secretion of this protective mucus Superficial gastric epithelial cells secrete bicarbonate ions, which neutralize the acid in the stomach, raising pH, and therefore preventing acid-mediated damage.
  8. The demonstrate reflux by determining pH level in esophagus
  9. Of the 20-40% of patients that experience heartburn, 30-80% of those patients will have esophagitis.
  10. Simethicone is an anti-foaming agent that decreases the surface tension of gas bubbles , causing them to combine into larger bubbles in the stomach that can be passed more easily by burping
  11. Notice that the aluminum containing antacid can neutralize 3 hydrochloric acid molecules at a time. There is also no carbon dioxide production Notice the calcium containing product forms carbon dioxide, this is what gives antacids the belching and gas sensation associated with them
  12. Excessive use of antacids coupled with impaired renal function can cause electrolyte imbalances. This can lead to high calcium concentrations, which can lead to kidney stones or calcium calcification in other areas of the body (heart). Increases in Al concentration leads to aluminum toxicity. Will talk about acid-rebound phenomenon at the end, as all acid suppressants can cause this.
  13. Incidence of GERD can label a patient with asthma as ‘exacerbation-prone’ due to the ensuing inflammation associated with acid reflux. Acidic irritation of the esophageal epithelium leads to a metaplastic change from a normal squamous type epithelium to an intestinal-type, columnar lining (Barrett’s)
  14. 3 Drug combo: protonix 40 bid + clarithromycin 500mg BID + amoxicillin 1 gram Bid OR metronidazole 500mg BID)
  15. Fluid content is the principal determinant of stool volume and consistency Water accounts for 70-85% of stool weight The daily challenge for the gut is to extract water, minerals, and nutrients from the luminal contents, leaving enough liquid for proper expulsion of waste material via defecation. 2 types of movement: Propulsive: giant migrating contractions, propagate over extended lengths, evoke mass transfer of feces Non-propulsive (mixing) 8-9 liters of water enter the small bowel, 1-1.5 liters cross into the colon, but only 100mL of water is expelled via feces. 6
  16. Causes of constipation: Lack of dietary fiber Drugs Hormonal disturbances Neurogenic disorders
  17. Medications include opioids, NSAIDS, TCAs, anticholinergics (antihistamines, antiparkonsinisms, phenothiazines), CCBs, diuretics, clonidine
  18. Fiber rich diet : 20-30 grams daily
  19. Metamucil: 2.5-4 grams per dose (1-3 teaspoonfuls in 250mL juice), now in tablet form Methylcelluose and polycarbophil: 4-6 grams per day
  20. Bisacodyl: enteric coated tabs-takes 6 hours to work suppository for rectal administration, work within 30-60 minutes **should not be used for more than 10 days to avoid developing an atonic nonfunctioning colon Castor oil: the triglyceride is hydrolyzed in the small bowel by lipases into glycerol and ricinoleic acid (active), which stimulates the secretion of fluid and electrolytes and speeds transit time seldom recommended due to palatibility recommended dose: 15-60 mL for adults Senna: produce giant migrating colonic contractions and induce water and electrolyte secretion. laxative effect noted 6-12 hours after administration due to requiring activation in the colon
  21. DISCUSS ADVERSE EFFECTS Just like the antacids that contain Mg, accumulation of Mg and Phos can be symptomatic, even deadly in elderly patients with poor renal function Liquid: Magnesium hydroxide 400 mg/5 mL: 5-15 mL as needed up to 4 times/day  
  22. ADVERSE EFFECTS WITH MINERAL OIL: ASPIRATION PNA
  23. If diarrhea is occuring due to an infectious cause, must treat the underlying infection with antibiotics Most diarrhea is self-limiting, 72 hours in duration